Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma.
Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics (UK) for a novel small molevule against migraines.
Teva can now beef up its sales with a new drug from its own pipeline, as reslizumab (Cinqair) has received marketing approval from the FDA.
This treatment will be available for adult patients with severe asthma showing an eosinophilic phenotype – types of asthma in which the patients have high count of this type of white blood cell. This type is associated with more frequent symptoms and a higher risk of asthma attacks.
Reslizumab is a monoclonal antibody that binds interleukin-5, having an antagonistic effect.